Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases where current treatments are inadequate. Key clinical programs include Barzolvolimab (CDX-0159), a monoclonal antibody that targets the KIT receptor to inhibit its activity, being studied for chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis. Another candidate is CDX-622, a bispecific antibody that neutralizes thymic stromal lymphopoietin and depletes mast cells through stem cell factor starvation, targeting inflammatory diseases. Celldex is headquartered in Hampton, New Jersey.

Celldex Therapeutics is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol CLDX. The trading currency for its shares is the US Dollar (USD). As a US-based company, its stock is traded in the United States, providing investors with exposure to the biotechnology sector through this exchange.

Celldex Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. Biotechnology companies like Celldex focus on using biological processes and living organisms to develop drugs and therapies. In Celldex's case, it specializes in therapeutic antibodies for severe inflammatory, allergic, autoimmune, and other diseases, targeting mast cell mediated conditions.

Celldex Therapeutics is headquartered in Hampton, New Jersey, United States. The company primarily serves the US market, as indicated by its country and region designation. Its drug development programs target diseases such as chronic urticarias, prurigo nodularis, eosinophilic esophagitis, atopic dermatitis, and other inflammatory conditions, addressing unmet medical needs in these therapeutic areas.